REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Clinical trial NCT03690869 · TERMINATED

Trial details

NCT number: NCT03690869
Sponsor: Regeneron Pharmaceuticals
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Relapsed Solid Tumor Refractory Solid Tumor Relapsed Central Nervous System Tumor Refractory Central Nervous System Tumor Diffuse Intrinsic Pontine Glioma High Grade Glioma

Start date: 2018-09-24
Primary completion: 2023-05-10
Enrollment: 57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.